ArticleFrontiers in oncology2026
The prognostic value of peripheral blood inflammatory markers in patients with HER2-positive metastatic breast cancer treated with pyrotinib.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Different peripheral blood markers have been reported to be involved in different stages of breast cancer development and metastasis. However, the association between NLR, LDH and prognosis of pyrotinib in HER2-positive metastatic breast cancer (mBC) remains unknown. Methods: We collected the clinical data and blood test results of 113 patients with HER2-positive mBC who were treated with pyrotinib at Chongqing University Cancer Hospital. The clinical data and blood test indexes were collected, and the ROC curve determined the optimal cut-off value. Kaplan-Meier survival curve and Cox regression model was used to analyze the effect of different levels of NLR and LDH before T-DM1 treatment on the survival of patients. Results: The optimal cut-off value of NLR and LDH was 2.44 (p=0.027) and 216.5U/L (p=0.033), respectively. With a median follow-up of 49.0 months (95%CI: 44.2-53.8), the median PFS and OS were 12.0 months (95%CI: 8.9-15.1) and 36.0 months (95%CI: 30.12-41.88), respectively. High NLR was associated with only a trend toward worse PFS (low-NLR vs high-NLR: 14.0 months vs 11.0 months, p=0.095). While patients with low LDH had a significantly longer PFS (19.0 months) than patients with high LDH (10.0 months, p<0.001). Higher NLR or LDH were significantly correlated with shorter median OS (low-NLR vs high-NLR: not reach (NR) vs 33.0 months, p=0.021; low-LDH vs high-LDH: NR vs. 30.0 months, p=0.002). Multivariable models showed that LDH was the only covariate independently associated with worse PFS (p=0.002), while high LDH (p=0.021), high NLR (p=0.007) and postmenopause (p=0.034) were independently associated with worse OS. Conclusions: Serum NLR and LDH were prognostic risk factors for metastatic HER2 positive breast cancer patients treated with pyrotinib. Elevated NLR and LDH were associated with poor PFS and OS. Future data are needed to validate and update our results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.